NO20080993L - Fremgangsmate for a forbedre arvakenhet - Google Patents

Fremgangsmate for a forbedre arvakenhet

Info

Publication number
NO20080993L
NO20080993L NO20080993A NO20080993A NO20080993L NO 20080993 L NO20080993 L NO 20080993L NO 20080993 A NO20080993 A NO 20080993A NO 20080993 A NO20080993 A NO 20080993A NO 20080993 L NO20080993 L NO 20080993L
Authority
NO
Norway
Prior art keywords
inheritance
improving
procedure
imidazolylalkyl
pyridines
Prior art date
Application number
NO20080993A
Other languages
English (en)
Norwegian (no)
Inventor
Christian N Lavedan
Mihael H Polymeropoulos
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of NO20080993L publication Critical patent/NO20080993L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
NO20080993A 2005-07-29 2008-02-25 Fremgangsmate for a forbedre arvakenhet NO20080993L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70360405P 2005-07-29 2005-07-29
US73253605P 2005-11-02 2005-11-02
PCT/US2006/029112 WO2007016203A1 (fr) 2005-07-29 2006-07-26 Procede permettant d'ameliorer l'etat de veille

Publications (1)

Publication Number Publication Date
NO20080993L true NO20080993L (no) 2008-02-25

Family

ID=37708941

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080993A NO20080993L (no) 2005-07-29 2008-02-25 Fremgangsmate for a forbedre arvakenhet

Country Status (12)

Country Link
US (1) US20080280954A1 (fr)
EP (1) EP1919477B1 (fr)
JP (1) JP5017268B2 (fr)
KR (2) KR101187461B1 (fr)
AU (1) AU2006275824B2 (fr)
BR (1) BRPI0614701A2 (fr)
CA (1) CA2616177C (fr)
ES (1) ES2388876T3 (fr)
HK (1) HK1117402A1 (fr)
NO (1) NO20080993L (fr)
NZ (1) NZ565763A (fr)
WO (1) WO2007016203A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101394849A (zh) 2006-02-13 2009-03-25 Vanda制药公司 咪唑基烷基-吡啶的稳定的剂量制剂
KR101587394B1 (ko) * 2006-05-22 2016-01-21 반다 파마슈티칼즈, 인코퍼레이티드. 멜라토닌 효능제 치료
WO2009097414A1 (fr) * 2008-01-29 2009-08-06 Vanda Pharmaceuticals, Inc. Utilisation d'imidazolylalkyl-pyridines pour le traitement de troubles addictifs
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
KR102317399B1 (ko) 2012-01-26 2021-10-26 반다 파마슈티칼즈, 인코퍼레이티드. 일주기 리듬 장애의 치료
EP2861244B1 (fr) * 2012-06-14 2018-09-19 The Regents Of The University Of Michigan Traitement d'apnée du sommeil
CN105142630A (zh) 2012-12-18 2015-12-09 万达制药公司 昼夜节律紊乱的治疗
CN103087019B (zh) * 2013-02-06 2015-02-04 济南志合医药科技有限公司 一种他司美琼的制备方法
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2593809B1 (fr) * 1986-01-31 1988-07-22 Lafon Labor Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique
DE4131584A1 (de) * 1991-09-23 1993-03-25 Sandoz Ag Imidazolylmethyl-pyridine, ihre herstellung und anwendung als pharmazeutika
US5635521A (en) * 1991-09-23 1997-06-03 Sandoz Ltd. Imidazolylmethyl-pyridines
NZ330656A (en) 1996-03-08 1999-06-29 Takeda Chemical Industries Ltd Tricyclic compounds, their production and use
US20010034373A1 (en) * 2000-02-09 2001-10-25 Matthew Miller Low dose modafinil for enhancement of cognitive function
GB0009037D0 (en) 2000-04-13 2000-05-31 Novartis Ag Organic compounds
US20040048931A1 (en) * 2002-07-12 2004-03-11 Craig Heacock Modafinil pharmaceutical compositions
US7528172B2 (en) * 2003-01-21 2009-05-05 The Cooper Health System, Inc. Compositions and methods for improving recovery after general anesthesia

Also Published As

Publication number Publication date
US20080280954A1 (en) 2008-11-13
JP2009502945A (ja) 2009-01-29
WO2007016203A1 (fr) 2007-02-08
KR101146807B1 (ko) 2012-05-21
KR101187461B1 (ko) 2012-10-02
EP1919477A4 (fr) 2009-03-18
CA2616177A1 (fr) 2007-02-08
JP5017268B2 (ja) 2012-09-05
AU2006275824B2 (en) 2010-12-16
KR20080033322A (ko) 2008-04-16
EP1919477A1 (fr) 2008-05-14
EP1919477B1 (fr) 2012-07-11
CA2616177C (fr) 2012-05-01
KR20110011748A (ko) 2011-02-08
BRPI0614701A2 (pt) 2011-04-12
HK1117402A1 (en) 2009-01-16
NZ565763A (en) 2010-12-24
ES2388876T3 (es) 2012-10-19
AU2006275824A1 (en) 2007-02-08

Similar Documents

Publication Publication Date Title
NO20080993L (no) Fremgangsmate for a forbedre arvakenhet
WO2011133875A3 (fr) Composés inhibiteurs de métalloenzyme
MX2010002732A (es) Inhibidores de f1f0-atpasa y metodos relacionados.
MX2009007944A (es) Compuestos y composiciones de purina como inhibidores de quinasa para el tratamiento de enfermedades relacionadas con plasmodium.
EA201170521A1 (ru) Новые соединения
MX2013015158A (es) Compuestos inhibidores de metaloenzima.
MX2009006536A (es) Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
PL2134704T3 (pl) Związki i kompozycje pełniące rolę modulatorów aktywności GPR119
EA201270049A1 (ru) Дизамещенные фталазиновые антагонисты пути hedgehog
TW200745109A (en) Pyrrolo-pyridine kinase modulators
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
EA200970737A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
WO2012064943A3 (fr) Composés inhibiteurs de métalloenzymes
MY164646A (en) Nicotine lozenge compositions
WO2007115821A3 (fr) Composés organiques
WO2011082245A3 (fr) Composés inhibiteurs de métallo-enzyme
DE602007010664D1 (de) P53 aktivierende benzoylharnstoff- und benzoylthioharnstoff-verbindungen
ATE478863T1 (de) Heterotetracyclische verbindungen als tpo- mimetica
MX2008013196A (es) 5-amido-2-carboxiamida-indoles.
TW200736233A (en) Cyclohexyl piperazinyl methanone derivatives
NO20082298L (no) Kaliumkanalinhibitorer
UA102250C2 (ru) Двухзамещенные фталазины - антагонисты проводящего пути hedgehog
TW200700064A (en) Novel compounds

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application